{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:54:56Z","timestamp":1794048896695,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005963","name":"LAM Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.rmed.2020.105898","type":"journal-article","created":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T11:20:43Z","timestamp":1581160843000},"page":"105898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex"],"prefix":"10.1016","volume":"163","author":[{"given":"Vera P.","family":"Krymskaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Courtwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Fleck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Dorgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kotloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis X.","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryl","family":"Kreider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2020.105898_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev-med-050715-104245","article-title":"Lymphangioleiomyomatosis: a monogenic model of malignancy","volume":"68","author":"Krymskaya","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.rmed.2020.105898_bib2","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1164\/rccm.201607-1384ST","article-title":"Official American thoracic society and japanise respiratory society clinical practice guidlines: lymphangioleiomyomatosis diagnosis and management","volume":"194","author":"McCormack","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2020.105898_bib3","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1172\/JCI58709","article-title":"Lymphangioleiomyomatosis\u2014a wolf in sheep's clothing","volume":"122","author":"Henske","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.rmed.2020.105898_bib4","doi-asserted-by":"crossref","first-page":"30958","DOI":"10.1074\/jbc.M202678200","article-title":"Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis","volume":"277","author":"Goncharova","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.rmed.2020.105898_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1165\/rcmb.2005-0374OC","article-title":"Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis","volume":"34","author":"Goncharova","year":"2006","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.rmed.2020.105898_bib6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2020.105898_bib7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2020.105898_bib8","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","article-title":"Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial","volume":"17","author":"Davies","year":"2011","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.rmed.2020.105898_bib9","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2020.105898_bib10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1183\/09031936.00210714","article-title":"Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study","volume":"46","author":"Goldberg","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2020.105898_bib11","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1083\/jcb.200405130","article-title":"TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase","volume":"167","author":"Goncharova","year":"2004","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.rmed.2020.105898_bib12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1165\/rcmb.2005-0300OC","article-title":"Abnormal smooth muscle cell growth in LAM: role for tumor suppressor TSC2","volume":"34","author":"Goncharova","year":"2006","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.rmed.2020.105898_bib13","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1128\/MCB.01061-10","article-title":"mTORC2 is required for proliferation and survival of TSC2-null cells","volume":"31","author":"Goncharova","year":"2011","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.rmed.2020.105898_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10555-008-9166-3","article-title":"The cytoskeleton and cancer","volume":"28","author":"Hall","year":"2009","journal-title":"Canc. Metastasis Rev."},{"key":"10.1016\/j.rmed.2020.105898_bib15","doi-asserted-by":"crossref","first-page":"154ra134","DOI":"10.1126\/scitranslmed.3003840","article-title":"Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM)","volume":"4","author":"Goncharova","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.rmed.2020.105898_bib16","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1164\/rccm.201607-1384ST","article-title":"Official American thoracic society\/Japanese respiratory society clinical practice guidelines: lymphangioleiomyomatosis diagnosis and management","volume":"194","author":"McCormack","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2020.105898_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2020.105898_bib19","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1165\/rcmb.2013-0203RC","article-title":"Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2\u2013Null cell growth and signaling","volume":"49","author":"Atochina-Vasserman","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.rmed.2020.105898_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2210-9-8","article-title":"Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models","volume":"9","author":"Lee","year":"2009","journal-title":"BMC Pharmacol."},{"key":"10.1016\/j.rmed.2020.105898_bib21","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1158\/1535-7163.MCT-09-0055","article-title":"Renal and liver tumors in Tsc2+\/\u2212 mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor","volume":"8","author":"Finlay","year":"2009","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.rmed.2020.105898_bib22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1124\/jpet.113.203141","article-title":"Chromatin remodeling by rosuvastatin normalizes TSC2-\/meth cell phenotype through the expression of tuberin","volume":"345","author":"Lesma","year":"2013","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.rmed.2020.105898_bib23","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2337\/db09-1602","article-title":"Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage","volume":"59","author":"Chakrabarti","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.rmed.2020.105898_bib24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1378\/chest.14-0758","article-title":"Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis","volume":"147","author":"Taveira-DaSilva","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2020.105898_bib25","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/TP.0b013e3181910eb2","article-title":"Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation","volume":"86","author":"Aliabadi","year":"2008","journal-title":"Transplant"},{"key":"10.1016\/j.rmed.2020.105898_bib26","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/ndt\/gfq157","article-title":"Rhabdomyolysis and acute kidney injury secondary to concomitant use of fluvastatin and rapamycin in a renal transplant recipient","volume":"25","author":"Basic-Jukic","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.rmed.2020.105898_bib27","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.rmed.2020.105898_bib28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"40","author":"Pasternak","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.rmed.2020.105898_bib29","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circ"},{"key":"10.1016\/j.rmed.2020.105898_bib30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.chest.2017.05.012","article-title":"Long-term effect of sirolimus on serum vascular endothelial growth factor D levels in patients with lymphangioleiomyomatosis","volume":"153","author":"Taveira-DaSilva","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2020.105898_bib31","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1513\/AnnalsATS.201605-335OC","article-title":"Efficacy and safety of long-term Sirolimus therapy for Asian patients with Lymphangioleiomyomatosis","volume":"13","author":"Takada","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.rmed.2020.105898_bib32","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1164\/rccm.201405-0918OC","article-title":"Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis","volume":"190","author":"Yao","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2020.105898_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180939","article-title":"Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study","volume":"12","author":"Bissler","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.rmed.2020.105898_bib34","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1183\/09031936.00012709","article-title":"Statins in lymphangioleiomyomatosis: a word of caution","volume":"34","author":"El-Chemaly","year":"2009","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2020.105898_bib35","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.vph.2005.11.007","article-title":"Angiogenic transcriptome of human microvascular endothelial cells: effect of hypoxia, modulation by atorvastatin","volume":"44","author":"Loboda","year":"2006","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.rmed.2020.105898_bib36","first-page":"631","article-title":"Statin therapy: review of safety and potential side effects","volume":"32","author":"Ramkumar","year":"2016","journal-title":"Acta Cardiol. Sin."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112030038X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112030038X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:58:52Z","timestamp":1760615932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095461112030038X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":35,"alternative-id":["S095461112030038X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2020.105898","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2020.105898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105898"}}